Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Selumetinib

ebd288d0-1f5e-5d40-9506-7ad4b5f13342 · FDA Approved · targets MEK1, MEK2

Selumetinib

MeasuredReference

Selumetinib has no high-confidence primary targets in the catalog. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

No high-confidence primary targets.

Top hallmarks

  • tumor promoting inflammation765
  • proliferation627
  • evading apoptosis584

Top pathways disrupted

  • pi3k akt mtor signaling1.2k
  • apoptosis1.0k
  • apical junction960

Resistance landscape — Selumetinib

MeasuredReference

1 known oncogenic variants exist on Selumetinib's top targets — see detail for inhibition impact.

Open in new tab